Literature DB >> 7427959

Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites.

A E Wakeling, S R Slater.   

Abstract

In female patients treated with tamoxifen (T), the major metabolite of T in serum is N-desmethyltamoxifen (N-d-Me T). The serum concentration of d-Me T may equal or exceed that of T, and 4-hydroxytamoxifen (4-OH T) is present in much lower concentration (< 10% that of T). The biologic properties and estrogen-receptor binding affinity of T and its desmethyl and 4-hydroxy metabolites have been compared. In competition studies with the rat uterus estrogen receptor at 0 degrees C and 25 degrees C, the relative affinities of T and d-Me T were similar, and their apparent affinity decreased when the incubation temperature was increased (38.2, 21.0 and 1.8, 1.1, respectively at 0 degrees C and 25 degrees C; 17 beta-estradiol = 100). In contrast, 4-OH T was a more potent inhibitor of estradiol binding (110 and 188 at 0 degrees C and 25 degrees C and its apparent affinity increased, rather than decreased, when the incubation temperature was raised from 0 degrees C to 25 degrees C. These differences in receptor binding were not reflected in biologic activity; all three compounds were potent antiestrogens of approximately equal activity in the rat. In patients, the pharmacologic effect of T may be due, in part, to d-Me T, but it is unlikely that 4-OH T plays a major role because of its relatively low serum concentration. The antiestrogenic potencies of T, d-Me T, and 4-OH T are similar, so the extent of metabolism in individual patients is unlikely to influence clinical response to tamoxifen therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7427959

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  17 in total

1.  Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer.

Authors:  Leticia B A Rangel; Jodi L Taraba; Christopher R Frei; Lon Smith; Gladys Rodriguez; John G Kuhn
Journal:  Breast Cancer Res Treat       Date:  2014-11-14       Impact factor: 4.872

2.  A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?

Authors:  Daniel F Hayes; Vered Stearns; James Rae; David Flockhart
Journal:  J Natl Cancer Inst       Date:  2008-04-29       Impact factor: 13.506

3.  The effect of estradiol on the sebaceous gland of the hamster ear and its antagonism by tamoxifen.

Authors:  G Schäfer; W Krause
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

4.  Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer.

Authors:  Changde Zhang; Qiu Zhong; Qiang Zhang; Shilong Zheng; Lucio Miele; Guangdi Wang
Journal:  Breast Cancer Res Treat       Date:  2015-06-14       Impact factor: 4.872

Review 5.  Antiestrogens--tamoxifen, SERMs and beyond.

Authors:  K Dhingra
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 6.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

7.  CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.

Authors:  Jean E Abraham; Mel J Maranian; Kristy E Driver; Radka Platte; Bolot Kalmyrzaev; Caroline Baynes; Craig Luccarini; Mitul Shah; Susan Ingle; David Greenberg; Helena M Earl; Alison M Dunning; Paul D P Pharoah; Carlos Caldas
Journal:  Breast Cancer Res       Date:  2010-08-23       Impact factor: 6.466

8.  Tamoxifen (Nolvadex) therapy--radionale for loading dose followed by maintenance dose for patients with metastatic breast cancer.

Authors:  P M Wilkinson; G G Ribiero; H K Adam; J V Kemp; J S Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

Review 9.  Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

10.  Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma.

Authors:  T Toko; J Shibata; Y Sugimoto; H Yamaya; M Yoshida; K Ogawa; E Matsushima
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.